Key result
Distinct lipid metabolite profiles accurately differentiate women with RA and SLE from healthy controls.
Why the study?
Rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases linked to chronic inflammation and cardiovascular risk, but metabolic alterations and lipid biomarkers in these patients remain to be identified.
Case-Control
Specific lipid metabolites demonstrate high predictive performance in distinguishing RA and SLE patients from healthy controls and correlate with inflammation and HDL levels, suggesting potential as biomarkers for cardiovascular risk.
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are autoimmune diseases associated with chronic inflammation and cardiovascular risk. This study aimed to identify metabolic alterations in Colombian women with RA and SLE to discover potential biomarkers. Plasma samples were analyzed using LC-QTOF-MS and GC-QTOF-MS. Correlation network analysis assessed relationships between metabolites, cytokines, and HDL levels. A generalized linear model (GLM) combined metabolite scores, and ROC analysis evaluated their predictive performance. Significant metabolic changes were observed, including decreased phospholipids and sphingolipids, and increased glycerolipids in RA and SLE compared to healthy controls. The metabolite-cytokine network revealed correlations between FA 18:0 and DG 37:7 with cytokines, linking lipid metabolism to inflammation. PS O-40:3 and FA 18:0 in RA and PC O-28:0 and DG 37:7 in SLE distinguished patients from healthy controls. The combination of PS O-40:3 and FA 18:0 in RA (AUC = 0.997) and PC O-28:0 and DG 37:7 in SLE (AUC = 0.949) demonstrated high predictive performance. PE O-42:5 was positively correlated with HDL, suggesting a potential protective role against cardiovascular disease. These findings highlight lipid metabolism's role in RA and SLE and support specific metabolites as biomarkers for disease differentiation, inflammation, and cardiovascular risk. These insights could lead to improved diagnostics and targeted treatments for these autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Duarte-Delgado et al. (2025) conducted a case-control in Rheumatoid arthritis and systemic lupus erythematosus. Rheumatoid arthritis and systemic lupus erythematosus vs. Healthy controls was evaluated on Metabolite scores for distinguishing patients from healthy controls. Specific lipid metabolites distinguished Colombian women with RA (PS O-40:3 and FA 18:0; AUC = 0.997) and SLE (PC O-28:0 and DG 37:7; AUC = 0.949) from healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: